missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human CHMP5 (aa 2-68) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (99%), Rat (99%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-60156 (PA5-60156. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
CHMP5 belongs to the chromatin-modifying protein/charged multivesicular body protein family. These proteins are components of ESCRT-III, a complex involved in degradation of surface receptor proteins and formation of endocytic multivesicular bodies. Some CHMPs have both nuclear and cytoplasmic/vesicular distributions, and one such CHMP, CHMP1A, is required for both MVB formation and regulation of cell cycle progression.
Specifications
Specifications
| Accession Number | Q9NZZ3 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 51510 |
| Name | Human CHMP5 (aa 2-68) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2210412K09Rik; apoptosis-related protein PNAS-2; AW545668; C9orf83; CGI-34; Charged multivesicular body protein 5; CHMP5; chromatin modifying protein 5; chromatin-modifying protein 5; HGNC:26942; HSPC177; hVps60; likely ortholog of H. sapiens SNF7 domain containing 2; PNAS-114; PNAS-2; SNF7 domain containing 2; SNF7 domain-containing protein 2; SNF7DC2; Vacuolar protein sorting-associated protein 60; Vps60 |
| Common Name | CHMP5 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction